Rebecca Harris

Rebecca Harris

Auto-generated profile, based on publicly available information

Rebecca Harris

Department of Pathology, University of Cambridge, Cambridge, UK 1

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Molecular Cell
Verified
Journal Article
Closed access
JSJia Z. Shen
Jia Z. Shen
ZQZhixin Qiu
Zhixin Qiu
QWQiulian Wu
Qiulian Wu
GZGuoxin Zhang
Guoxin Zhang
RHRebecca Harris
Rebecca Harris
CSCharles Spruck
Charles Spruck

7 June 2022 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
RHRebecca Harris
Rebecca Harris
MYMing Yang
Ming Yang
CSChristina Schmidt
Christina Schmidt
CRChloe Royet
Chloe Royet
SSSarbjit Singh
Sarbjit Singh
HLHeike Laman
Heike Laman
Fbxo7 is associated with cancer and Parkinson’s disease. Although Fbxo7 recruits substrates for SCF-type ubiquitin ligases, it also promotes Cdk6 activation in a ligase-independent fashion. We discovered PFKP, the gatekeeper of glycolysis, in a screen for Fbxo7 substrates. PFKP is an essential Cdk6 substrate in some T-ALL cells. We investigated the molecular relationship between Fbxo7, Cdk6, and PFKP, and the effect of Fbxo7 on T cell metabolism, viability, and activation. Fbxo7 promotes Cdk6-independent ubiquitination and Cdk6-dependent phosphorylation of PFKP. Importantly, Fbxo7-deficient cells have reduced Cdk6 activity, and hematopoietic and lymphocytic cells show high expression and significant dependency on Fbxo7. CD4+ T cells with reduced Fbxo7 show increased glycolysis, despite lower cell viability and activation levels. Metabolomic studies of activated CD4+ T cells confirm increased glycolytic flux in Fbxo7-deficient cells, alongside altered nucleotide biosynthesis and arginine metabolism. We show Fbxo7 expression is glucose-responsive at the mRNA and protein level and propose Fbxo7 inhibits PFKP and glycolysis via its activation of Cdk6.

1 January 1998 in Journal of Chemical Research
Verified
Journal Article
Closed access
PDF file
RHRebecca C. Harris
Rebecca C. Harris
ACAnnabel L. Cutter
Annabel L. Cutter
Kira WeissmanKira Weissman
Kira Weissman
Ulf HanefeldUlf Hanefeld
Ulf Hanefeld
MTMa´ire C. Timoney
Ma´ire C. Timoney
JSJames Staunton
James Staunton
The four stereoisomers of 3-hydroxy-2-methylpentanoic acid (1a–d) and the structurally modified acids 1e–j have been synthesised enantiospecifically and converted into p-nitrophenyl ester and thioester derivatives; as the activated derivatives; they are available for investigations into the substrate selectivity of polyketide synthase (PKS) domains.

1 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
RHRebecca Harris
Rebecca Harris
SRSuzanne Randle
Suzanne Randle
HLHeike Laman
Heike Laman
Fbxo7 is a key player in the differentiation and function of numerous blood cell types, and in neurons, oligodendrocytes and spermatocytes. In an effort to gain insight into the physiological and pathological settings where Fbxo7 is likely to play a key role, we sought to define the transcription factors which direct FBXO7 expression. Using sequence alignments across 28 species, we defined the human FBXO7 promoter and found that it contains two conserved regions enriched for multiple transcription factor binding sites. Many of these have roles in either neuronal or haematopoietic development. Using various FBXO7 promoter reporters, we found ELF4, Pax5 and c-Myb have functional binding sites that activate transcription. We find endogenous Pax5 is bound to the FBXO7 promoter in pre-B cells, and that the exogenous expression of Pax5 represses Fbxo7 transcription in early pro-B cells.